Purpose and Discussion Topics
The goal of the forum was to recommend activities and programs that AMCP can promote to improve pain management, prevent OUD, and improve OUD treatment outcomes. In view of that goal, the following topics were discussed: 1. From managed care and patient perspectives, how do we not repeat the past? 2. Are our organizations maximizing internal and external sources (including MTM) and working collaboratively to prevent OUD? 3. Are our organizations managing internal and external resources (e.g., behavioral health, physical therapy, and treatment centers) effectively to treat OUD? 4. What would external partners and patients ask you to change about your approach?
■■ Opioid Use Disorder as a Public Health Crisis
The scope of OUD was reviewed at the forum by Speaker Michael Botticelli, director of the White House Office of National Drug Control Policy. 7 Of the 41,340 drug overdose deaths in 2011 in the United States, 41% involved prescription drugs, with the vast majority (71%) being opioid analgesics. 8 Another 22% involved cocaine (11%) and heroin (11%). A 2007 study estimated costs for prescription drug abuse of $55.7 billion, including $25 billion in direct health care costs and $5.1 billion in criminal justice costs. 2 Other studies found that the average individual abusing opioids has annual direct health care costs that are 8.7 times higher than nonabusers. 5 While only a small fraction of nonmedical pain reliever (NMPR) users (3.6%) initiated heroin use, prescription opioid use is a risk factor for heroin use. Approximately 80% of heroin users used NMPRs before heroin initiation. 9 Recent research shows that individuals who formerly abused prescription opioids are motived to move to heroin because of price, availability, ease of use, and enhanced effects. 
U.S. National Drug Control Strategy 2014
In response to the current public health crisis, the Obama Administration's U.S. National Drug Control Strategy emphasizes preventing drug use through education.
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Part of President Barack Obama's science-based plan is to reform drug policy by (a) expanding access to treatment for Americans struggling with addiction, (b) reforming our criminal justice system, and (c) supporting Americans in recovery.
Comparative effectiveness of opioids versus nonopioid
therapies on pain, function, and quality of life. 3. Comparative effectiveness of short-versus long-term opioid use on outcomes related to pain, function, quality of life, risk of overdose, addiction, and abuse.
■■ Pain Management Should Emphasize OUD Prevention
Through discussion, the speakers and panelists defined the starting point for preventing OUD as the understanding that all opioid users are at risk, not just chronic pain patients. 14, 15 Data from the Office of National Drug Control Policy demonstrate that friends and relatives remain a major source of opioids for nonmedical use but physician prescribing accounts for 17%-26% of the sourcing (Figure 1 ).
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Role of P&T Committees
Given this starting point, Speaker Jessica Daw, director of Clinical Pharmacy at the University of Pittsburgh Medical Center (UPMC) Health Plan recommended that pharmacy and therapeutics (P&T) committees rely on evidence-based medicine to drive their decisions about pain treatment. 17 In the past, Daw posited, we relied on pain guidelines that were supported by a low level of evidence for long-term opioid use. Now, she noted that while abuse-deterrent formulations are coming to the market, there are limited well-designed studies proving that these formulations have reduced the likelihood of OUD. She and other panelists recommended that if these new products are added to coverage or to formularies, P&T committees should require reviews of real-world data after implementation.
The UPMC P&T Committee has implemented a variety of prevention strategies, including the following: • Limits on days supply, quantity, and prescriptions.
• Prior authorization, including compounded products and long-acting products.
• Concurrent drug utilization review (DUR) and fraud waste and abuse programs that target high-user patients, pharmacies, and physicians. These programs included targets identified by the Centers for Medicare & Medicaid Services (CMS) Overutilization Monitoring System (OMS).
• Lock-in programs, including beneficiary-level point-ofservice edits.
• Management of nonparticipating providers.
UPMC also launched a physician toolkit, developed with the assistance of network pain specialists that includes the following:
• Patient assessment guidelines.
• Summary of pain etiology and treatment options.
• Acute pain strategies and resources for management and follow-up.
• Chronic pain strategies and resources for management and follow-up.
The U.S. National Drug Control Strategy presents 4 objectives for preventing prescription drug abuse: (1) education, (2) prescription drug monitoring programs (PDMP), (3) proper disposal of medication, and (4) enforcement.
To accomplish these objectives, more research is needed on effective strategies for reducing overdose and the prevalence of substance use disorders.
The Perfect Storm
Speaker Beth Tanzman, assistant director of Vermont Blueprint for Health, explored the factors that have contributed to the current epidemic of unintentional overdose deaths to which opioid analgesics contribute. 12 The health care community usually attributes the prevalence of OUD to an overreliance on opioids for pain relief. The following additional contributing factors were identified:
• Increasing rates of opioid prescribing.
•. Inadequate network capacity for OUD treatment.
• High health care expenditures for OUD treatment.
• Poor patient outcomes with OUD treatment.
• Program and funding silos.
• Lack of an evidence-based medicine approach to pain management and OUD.
AHRQ Systematic Review
In considering an evidence-based medicine approach, speakers and panelists discussed the Agency for Healthcare Research and Quality (AHRQ) 2014 systematic review "The Effectiveness and Risks of Long-Term Opioid Treatment of Chronic Pain." 13 This review emphasized that lack of strong evidence has hindered our response to "the dramatic increase in overdose deaths associated with opioids." In particular, this report noted that evidence is insufficient in these following areas: 1. Effectiveness of risk prediction tools at predicting risk for, reducing the rates of, or improving outcomes related to opioid overdose, addiction, abuse, or misuse. 2. Effectiveness of risk mitigation strategies, including abuse deterrent formulations, urine drug screenings, prescription drug monitoring program data, monitoring instruments, and opioid management plans. 3. Comparative effectiveness of treatment options for opioid addiction lack the rigor necessary to provide definitive pathways.
The AHRQ review also noted that there is limited evidence to support the abundant use of prescription opioids. It found the strength of evidence low for the following: 1. Effectiveness of long-term opioid therapy versus placebo for more than 1 year.
• Tools for proper documentation and pain management.
• Multidisciplinary team support and referral options.
• Equi-analgesic dosing chart.
Beyond P&T Committees
Speaker Thomas Kowalski, director of Clinical Pharmacy for Blue Cross Blue Shield of Massachusetts (BCBSMA), detailed a systemwide approach that BCBSMA took with its OUD prevention efforts. BCBSMA convened advisory groups that consisted of network pain management providers, addiction experts, pharmacists, and primary care providers to define best practices in opioid management. 18 Three key opioid interventions were identified: quantity level limits and prior authorization (PA) requirements for opioids, medication-assisted treatment (MAT) drugs, and laboratory testing. The specific restrictions included the following: • A 15-day supply limit on initial prescriptions of shortacting opioids. Patients with cancer and terminal illness are excluded. PA is required for subsequent opioid prescriptions that exceed a 30-day supply in a rolling 60-day period. Authorization is based on existence of evidence-based opioid-prescribing elements (i.e., informed consent on risks, risk assessment for addiction, provider-patient opioid agreement, defined limited prescribing group, and identification of single pharmacy or chain).
• PAs grant access to a 15-day supply of all short-acting opioids on BCBSMA formularies. Additional 15-day supplies within 60 days are allowed to a maximum of a 30-day supply in a rolling 60-day period. Beyond this, an authorization is required, but if a PA is not available at the point of sale, the member receives a 3-day supply of the short-acting opioid. This allows sufficient time for an authorization to be obtained.
• For long-acting opioids, providers must document that the elements of evidence-based opioid prescribing were followed and give a trial of short-acting opioids (or a reason why this is inappropriate).
• MAT drugs (e.g., buprenorphine) require PA with physician verification of the evidence-based elements of opioid prescribing and assessment of a member's access to behavioral health support.
To support these strategies, BCBSMA uses the CMS OMS quarterly reports and monthly provider reporting. The OMS provides quarterly reports to Part D plan sponsors on beneficiaries who received opioids in excess of 120 milligrams morphine equivalent dose for 90 consecutive days from 4 or more prescribers and 4 or more pharmacies in a 1-year period, and acetaminophen use that exceeds a daily dose of 4 grams for 30 days in a 6-month period. 19 Provider reports detail any member receiving more than 2 prescriptions from more than 2 prescribers and more than 2 pharmacies. These combined strategies dropped members receiving opioids by 7.2% and opioid claims by 8.3% in a 12-month period.
Speakers and panelists noted that, while slow in coming, U.S. Food and Drug Administration (FDA) prevention strategies are having some impact. The FDA enacted risk evaluation and mitigation strategies (REMS) for extended-release/longacting opioids; whether there are better ways to look at addiction and overdose rates and other outcome measures is being asked. 20, 21 Generally, speakers and panelists agreed that the FDA-recommended rescheduling of all hydrocodone products to Schedule II could have a positive impact on OUD decline.
Speakers and participants discussed other recent federal and state calls to action that have been experiencing some success. Prescription drug monitoring programs (PDMP) are being operationalized in every state, with interoperability among states. Tennessee's PDMP law requiring prescribers to access the PDMP before prescribing opioids to a new patient demonstrates the potential for PDMPs: the number of high opioid users (defined as a person who used 5 prescribers and 5 pharmacies in a 90-day period) decreased by 47%. 22 Additionally, promotion of lock-in programs, with the understanding that optimal program design and coordination with other OUD policies should continue to be explored, was advocated. 23 Similarly, the CMS OMS, instituted partly in response to GAO-11-699-which found that 170,000 beneficiaries received medicines from 5 or more prescribers 24 -is showing a reduction in the overuse of opioids and acetaminophen in Medicare Part D. 19 
■■ Identifying and Treating Opioid Use Disorder
The scope of illicit drug use in the United States is alarming. An estimated 8.7 million persons aged 12 years or older (3.3%) were current users of illicit drugs other than marijuana in 2013. 25 The majority (2.5%, 6.5 million) of these users were nonmedical users of psychotherapeutic drugs, including 4.5 million users of pain relievers and tranquilizers (1.7%) and stimulants (0.5%). According to Speaker Michael Duggan, founder of Wicked Sober, a support group for patients with OUD, patient denial is another equally concerning stumbling block to our ability to stem this epidemic. 15 This concern was confirmed by the 2013 National Survey on Drug Use and Health: among illicit drug users, 95% did not feel they needed treatment. 25 Only 1.6% of illicit users thought they needed treatment and made an effort, and an additional 2.9% felt they needed treatment but did not make an effort.
Duggan also emphasized that patient willingness to accept help often has a very narrow window-speed to treatment and the difficulty in navigating the health care system are important outcome determinants. Also important is acknowledgement by health care providers of our role in creating the epidemic and open discussion on how the stigma of addiction delays recognition and treatment for patients and their families. 15 Speaker Botticelli indicated that the White House is on record as supporting the following OUD treatment paradigms: 7 • Supporting MAT. The premise is that medication withdrawal and psychosocial treatment alone without medication show high rates of relapse.
• Working to expand access to evidence-based treatment by creating an inventory of treatment availability and working within Affordable Care Act and state-run health marketplaces to ensure proper resourcing.
The Vermont Blueprint for Health was presented by Speaker Tanzman as an example of best practices for the identification and treatment of OUD. 12 In the Vermont Hub and Spoke model for opioid addiction, 26 the "spokes" are usual care with team-based care for officebased practices (physicians and community health teams comprising nurse care managers, health coaches, social workers, and behavioral health clinicians). The "hubs" care for people with complex OUD disorders and mental health comorbidities (e.g., methadone treatment centers; Figure 2 ). Speaker Daw discussed UPMC's MAT initiatives, which included the following: 14 • Letters to providers notifying them of expanded patient access to MAT and encouraging training in MAT. Requires MAT prescribers to work with licensed drug and alcohol treatment providers to establish a treatment plan for the patient.
• Following MAT guidelines by allowing for no narcotic fills within 90 days of a buprenorphine fill and tapering patients off benzodiazepines.
• UPMC Health Plan best practices: Pain management DUR.
Targets members in need of pain control by providing pharmacist and care management support.
■■ Forum Recommendations for AMCP
The speakers and panelists recommended that a robust educational awareness campaign is needed that states the capabilities and benefits of holistic approaches to pain management and OUD prevention and treatment. This campaign should include a transparent, all-encompassing educational effort that shows which best practices are supported by a high strength of evidence.
Components of the Educational Plan
Components of the proposed educational plan were presented as follows: 
■■ Conclusions
Addressing the persistent prescription drug abuse problem and its resultant high societal and economic costs requires the coordinated efforts and actions of all stakeholders. Efforts to improve pain management outcomes and reduce the potential for OUD should rely on demonstrated evidence and best practices. Grassroots efforts involving local providers, organizations, community resources, and patient advocates are needed. AMCP should promote a more holistic evidence-based approach to pain management and treatment of OUD. This approach should actively engage the patient in the decision process and include care coordination with medical, pharmacy, behavioral, and mental health aspects of organizations, seamlessly supported by a technology infrastructure.
